CD274 and neoplasm: Several additional transcripts, including EpCAM, CK19, NANOG, PROM1, TERT, CDH5, FAM83A, and PTHLH [146], as well as high expression levels of BCL2, CD274 (PD-L1), CDH1, EPCAM, FGFR1, FN1, KRT18, MET, and MUC1 [147], have been linked to reduced survival and aggressive tumor biology in NSCLC.